Menu

Pipeline Overview*

PRODUCT2 Indication Pre-clinical Phase 1/2 Phase 3 Commercial1
Talicia® H. pylori infection3
APPROVED BY U.S. FDA NOVEMBER 2019
Aemcolo® Travelers' Diarrhea4
U.S. EXCLUSIVE LICENSE
Donnatal® IBS and acute enterocolitis5
U.S. CO-PROMOTION
Mytesi® Non-infectious diarrhea in HIV/AIDS patients5
U.S. CO-PROMOTION
EnteraGam® Chronic diarrhea and loose stools7
U.S. EXCLUSIVE LICENSE
Esomeprazole Strontium DR Capsules GERD and other GI conditions6
U.S. COMMERCIALIZATION LICENSE
RHB-104 Crohn's disease
RHB-204 NTM infections
RHB-102
(Bekinda®)
Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
ABC294640
(Yeliva®)
Multiple indications
RHB-107 Oncology/GI
Other
RIZAPORT®
(RHB-103)
Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies
1 Talicia® planned to be launched in Q1/2020 in the U.S.
2 Bekinda® (RHB-102) and Yeliva® (ABC294640) are proposed tradenames which are subject to FDA review and approval
3 Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: here
4 Aemcolo® (rifamycin) is indicated for the treatment of travelers diarrhea caused by noninvasive strains of Escherichia Coli in adults For full prescribing information see: here

Company Profile

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on commercialization and development of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

Read more